Author | Patient numbers | “Gain” in HER2 | “Loss” of HER2 |
|---|
Giotta [8] | 20 | 5% | 5% |
Gancberg [9]: | | | |
Immunohistochemistry | 100 | 6% | - |
In situ hybridisation | 68 | 4% | 3% |
Nikura [10] | 182 | - | 24% |
Amir [11] | 83 | 8% (6/73) | 20% (2/10) |
Gong [12] | 60 | 1.6% | 1.6% |
Tapia [13] | 105 | 1.9% | 0.9% |
Fabi [14] | 137 | 8.7% | 1.5% |
Simon [15] | 122 | 2.2% | 6.5% |
Lindstrom [16] | 76 | 6.5% | 10.5% |
